US4432966A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating
Assignee: Sanofi Aventis France
•
Filing: 1982-08-31
•
Granted: 1984-02-21
•
Expires: 2002-08-31
Abstract
Abstract Coated compressed tablets for oral administration are disclosed which substantially desintegrate specifically at the level of the colon. The tablets comprise a compressed center piece containing an active agent which center piece is coated by a first coating layer which is comprised of a mixture of a pharmaceutically acceptable film-forming organic polymer material which is non-deteriorated by a neutral or alkaline aqueous medium and microcrystalline cellulose and a second coating layer which is comprised of a pharmaceutically acceptable enteric organic polymer coating material.
Inventors
- 👤 Paul Zeitoun
- 👤 Patrick Brisard
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 07:37
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/28; A61K9/2886
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
203 words
A compressed tablet for oral administration and disintegration in the colon which consists essentially of: (a) a microcrystalline cellulose-free compressed center piece containing an active agent; (b) a first coating layer amounting to between about 0.5% and about 10% by weight of that of the center, coating the compressed center piece and consisting essentially of a mixture of a pharmaceutically acceptable lower alkyl ether of a cellulose film-forming organic polymer material which is not deteriorated by a neutral or alkaline aqueous medium, and from about 30% to about 80% by weight of the first coating layer of microcrystalline cellulose; and (c) a second coating layer amounting to between about 2% to about 10% by weight of the center, coating the first coating layer and consisting essentially of a microcrystalline cellulose-free pharmaceutically acceptable enteric organic polymer coating material selected from the group consisting of cellulose acetylphthalate, hydroxypropylmethylcellulose phthalate, benzophenyl salicylate, cellulose acetosuccinate, copolymers of styrene and of maleic acid, formylated gelatin, salol, keratin, stearic acid, myristic acid, gluten, acrylic and methacrylic resins, and copolymers of maleic acid and phthalic acid derivatives; each of said coating layers containing a plasticizer selected from the group consisting of diethylphthalate, dibutylphthalate, propylene glycol, castor oil and mixtures thereof.
Claim 2
Dependent Claim
203 words
A compressed tablet for oral administration and disintegration in the colon which consists essentially of: (a) a microcrystalline cellulose-free compressed center piece containing an active agent; (b) a first coating layer amounting to between about 0.5% and about 10% by weight of that of the center, coating the compressed center piece and consisting essentially of a mixture of a pharmaceutically acceptable lower alkyl ether of a cellulose film-forming organic polymer material which is not deteriorated by a neutral or alkaline aqueous medium, and from about 30% to about 80% by weight of the first coating layer of microcrystalline cellulose; and (c) a second coating layer amounting to between about 2% to about 10% by weight of the center, coating the first coating layer and consisting essentially of a microcrystalline cellulose-free pharmaceutically acceptable enteric organic polymer coating material selected from the group consisting of cellulose acetylphthalate, hydroxypropylmethylcellulose phthalate, benzophenyl salicylate, cellulose acetosuccinate, copolymers of styrene and of maleic acid, formylated gelatin, salol, keratin, stearic acid, myristic acid, gluten, acrylic and methacrylic resins, and copolymers of maleic acid and phthalic acid derivatives; each of said coating layers containing a plasticizer selected from the group consisting of diethylphthalate, dibutylphthalate, propylene glycol, castor oil and mixtures thereof.
Claim 3
Dependent Claim
77 words
A method of orally administering a pharmacologically active ingredient or a diagnostic agent for release in the colon, comprising the steps of orally administering a compressed tablet containing a pharmacologically active ingredient or a diagnostic agent to a subject having a colon needing treatment whereby said agent is not substantially released in the stomach or the small intestine and is practically entirely released in the colon, and wherein said compressed tablet is a tablet of claim 1.
Claim 4
Dependent Claim
14 words
The method of claim 2 wherein the active or diagnostic agent is barium sulphate.
Claim 5
Dependent Claim
20 words
The compressed tablet as defined in claim 1, wherein the film-forming material in the first coating layer is ethyl cellulose.
Claim 6
Dependent Claim
16 words
The compressed tablet as defined in claim 1, wherein the enteric coating material is cellulose acetylphthalate.
Claim 7
Dependent Claim
46 words
The compressed tablet as defined in claim 1 wherein the film-forming material of the first coating layer is ethyl cellulose, the enteric coating material is cellulose acetylphthalate and the plasticizer is selected from the group consisting of diethyl phthalate, dibutyl phthalate, propylene glycol, and mixtures thereof.
Claim 8
Dependent Claim
43 words
The method of claim 2 wherein the film-forming material in the first coating layer is ethyl cellulose, the enteric coating material is cellulose acetylphthalate and the plasticizer is selected from the group consisting of diethyl phthalate, dibutyl phthalate, propylene glycol and mixtures thereof.
References Cited (Backward Citations)
US2687367A
Cited
US2798024A
Cited
US2853420A
Cited
US2991226A
Cited
US2928770A
Cited
US3278519A
Cited
US3372132A
Cited
US3162541A
Cited
US3143472A
Cited
US3371015A
Cited
US3259537A
Cited
US3258354A
Cited
US3357845A
Cited
US3431338A
Cited
US3420931A
Cited
US3192118A
Cited
US3981984A
Cited
US3784683A
Cited
US3957523A
Cited
US4001390A
Cited
GB1538123A
Cited
US4193985A
Cited
US4274830A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-02-20 | 1987-08-22 | 1988-02-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-02-20 | 1991-08-22 | 1992-02-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-02-20 | 1995-08-22 | 1996-02-21 | $7700.00 | Window Closed / Lapsed |